Clinical Trial Update: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating talazoparib in advanced/metastatic breast cancer with BRCA mutations has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms

Drugs mentioned

• Talazoparib (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms, BRCA 1 Gene Mutation | Phase 3 | Status: COMPLETED | Results posted: 2018-10-03